Autoimmune skin diseases: Role of sex hormones, vitamin d, and menopause

Skin, Mucosa and Menopause: Management of Clinical Issues

Volumn , Issue , 2015, Pages 359-381

  Fairweather, Delisa ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84943647428     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-662-44080-3_26     Document Type: Chapter

References (250)

1. Jacobson DL, Gange SJ, Rose NR, Graham NMH. Epidemiology and estimated population burden of selected autoimmune disease in the United States. Clin Immunol Immunopathol. 1997;84:223-43.
2. Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathologic perspective. Am J Pathol. 2008;173:600-9.
3. Notkins AL. Pathogenic mechanisms in autoimmune disease. Autoimmun Rev. 2004;3(Suppl): S7-9.
4. Fairweather D, Frisancho-Kiss S, Njoku DB, Nyland JF, Kaya Z, Yusung SA, Davis SE, Frisancho JA, Barrett MA, Rose NR. Complement receptor 1 and 2 deficiency increases coxsackievirus B3-induced myocarditis and heart failure by increasing macrophages, IL-ip and immune complex deposition in the heart. J Immunol. 2006;176:3516-24.
5. Wahren-Herlenius M, Dorner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet. 2013;382:819-31.
6. Fairweather D, Petri MA, Coronado MJ, Cooper Jr LT. Autoimmune heart disease: role of sex hormones and autoantibodies in disease pathogenesis. Expert Rev Clin Immunol. 2012;8:269-84.
7. Carson DA, Chen PP, Fox RI, Kipps TJ, Jirik F, Goldfien RD, Silverman G, Radoux V, Fong S. Rheumatoid factor and immune networks. Ann Rev Immunol. 1987;5:109-26.
8. Newkirk MM. Rheumatoid factors: host resistance or autoimmunity? Clin Immunol. 2002;104:1-13.
9. Dorner T, Egerer K, Feist E, Burmester GR. Rheumatoid factor revisited. Curr Opin Rheumatol. 2004;16:246-53.
10. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356-61.
11. Zandman-Goddard G, Peeva E, Shoenfeld Y. Gender and autoimmunity. Autoimmun Rev. 2007;6:366-72.
12. Beeson PB. Age and sex associations of 40 autoimmune diseases. Am J Med. 1994;96:457-62.
13. Whitacre CC. Sex differences in autoimmune disease. Nat Immunol. 2001;2:777-80.
14. Gleicher N, Barad DH. Gender as a risk factor for autoimmune diseases. J Autoimmun. 2007;28:1-6.
15. Styrt B, Sugarman B. Estrogens and infection. Rev Infect Dis. 1991;13:1139-50.
16. Flanagan KL, Klein SL, Skakkebaek NE, Marriott I, Marchant A, Selin L, Fish EN, Prentice AM, Whittle H, Benn CS, Aaby P. Sex differences in the vaccine- specific and non-targeted effects of vaccines. Vaccine. 2011;16:2349-54.
17. Lang TJ. Estrogen as an immunomodulator. Clin Immunol. 2004;113:224-30.
18. Cook IF. Sexual dimorphism of humoral immunity with vaccines. Vaccine. 2008;26:3551-5.
19. Straub RH. The complex role of estrogens in inflammation. Endocr Rev. 2007;28:521-74.
20. Rubtsov A, Rubtsova K, Kappler JW, Marrack P. Genetic and hormonal factors in female-biased autoimmunity. Autoimm Rev. 2010;9:494-8.
21. Lahita RG. Sex hormones and immune function. In: Legato MJ, editor. Principles of gender-specific medicine. 2nd ed. MA: Elsevier; 2010. p. 615-26.
22. Wilder RL. Neuroendocrine-immune system interactions and autoimmunity. Annu Rev Immunol. 1995; 13:307-38.
23. Carreras E, Turner S, Frank MB, Knowlton N, Osban J, Centola M, Park CG, Simmons A, Alberola-lla J, Kovats S. Estrogen receptor signaling promotes dendritic cell differentiation by increasing expression of the transcription factor IRF4. Blood. 2010;115:238-46.
24. Khan D, Dai R, Karpuzoglu E, Ahmed SA. Estrogen increases, whereas IL-27 and IFN-gamma decrease, splenocyte IL-17 production in WT mice. Eur J Immunol. 2010;40:2549-56.
25. Wang Y, Cela E, Gagnon S, Sweezey NB. Estrogen aggravates inflammation in Pseudomonas aeruginosa pneumonia in cystic fibrosis mice. Respir Res. 2010;30:166.
26. Polanczyk MJ, Carson BD, Subramanian S, Afentoulis M, Vandenbark AA, Ziegler SF, Offner H. Cutting edge: estrogen drives expansion of the CD4 + CD25+ regulatory T-cell compartment. J Immunol. 2004; 173:2227-30.
27. Polanczyk MJ, Hopke C, Huan J, Vandenbark AA, Ziegler SF, Offner H. Enhanced FoxP3 expression and Treg cell function in pregnant and estrogen- treated mice. J Neuroimmunol. 2005;170:85-92.
28. Frisancho-Kiss S, Davis SE, Nyland JF, Frisancho JA, Cihakova D, Rose NR, Fairweather D. Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J Immunol. 2007;178:6710-4.
29. Xia X, Zhang S, Yu Y, Zhao N, Liu R, Liu K, Chen X. Effects of estrogen replacement therapy on estrogen receptor expression and immunoregulatory cytokine secretion in surgically induced menopausal women. J Reprod Immunol. 2009;81:89-96.
30. Pulendran B, Tang H, Manicassamy S. Programming dendritic cells to induce Th2 and tolergenic responses. Nat Immunol. 2010;11:647-55.
31. Dinesh RK, Hahn BH, Singh RP. PD-1, gender and autoimmunity. Autoimm Rev. 2010;9:583-7.
32. Sellner J, Kraus J, Awad A, Milo R, Hemmer B, Stuve O. The increasing incidence and prevalence of female multiple sclerosis- a critical analysis of potential environmental factors. Autoimmun Rev. 2011;10:495-502.
33. Papenfuss TL, Powell ND, McClain MA, Bedarf A, Singh A, Gienapp IE, Shawler T, Whitacre CC. Estriol generates tolergenic dendritic cells in vivo that protect against autoimmunity. J Immunol. 2011;186:3346-55.
34. Giron-Gonzalez JA, Moral FJ, Elvira J, Garcia-Gil D, Guerrero F, Gavilan I, Escobar L. Consistent production of a higher Th1: Th2 cytokine ratio by stimulated T cells in men compared with women. Eur J Endocrinol. 2000;143:31-6.
35. Giltay EJ, Fonk JC, von Blomberg BM, Drexhage HA, Schalkwijk C, Gooren LJ. In vivo effects of sex steroids in lymphocyte responsiveness and immunoglobulin levels in humans. J Clin Endocrinol Metab. 2000;85:1648-57.
36. Loria RM. Immune up-regulation and tumor apoptosis by androstene steroids. Steroids. 2002;67: 953-66.
37. Desai KV, Michalowska AM, Kondaiah P, Ward JM, Shih JH, Green JE. Gene expression profiling identifies a unique androgen-mediated inflammatory/immune signature and a PTEN (phosphatase and ten- sin homolog deleted on chromosome 10)-mediated apoptotic response specific to the rat ventral prostate. Mol Endocriniol. 2004;18:2895-907.
38. Miller VM. Why are sex and gender important to basic physiology, translational and individualized medicine? Am J Physiol Heart Circ Physiol. 2014;306: H781-8.
39. Dube SR, Fairweather D, Pearson WS, Felitti VJ, Anda RF, Croft JB. Cumulative childhood stress and autoimmune diseases in adults. Psychomatic Med. 2009;71:243-50.
40. Gharaee-Kermani M, Hatano K, Nozaki Y, Phan SH. Gender-based differences in bleomycin-induced pulmonary fibrosis. Am J Pathol. 2005;166:1593-606.
41. Pennell LM, Galligan CL, Fish EN. Sex affects immunity. J Autoimmun. 2012;38: J282-91.
42. Kato I, Toniolo P, Akhmedkhanov A, Koenig KL, Shore R, Zeleniuch-Jacquotte A. Prospective study of factors influencing the onset of natural menopause. J Clin Epidemiol. 1998;51:1271-6.
43. Jacobsen BK, Heuch I, Kvale G. Age at natural menopause and all-cause mortality: a 37-year follow-up of 19,731 Norwegian women. Am J Epidemiol. 2003; 157:923-9.
44. Harlow SD, Gass M, Hah JE, Lobo R, Maki P, Rebar RW, Sherman S, de Sluss PM, Villiers TJ. Executive summary of the stages of reproductive aging workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97:1159-68.
45. Vermeulen A. Declining androgens with age: an overview. In: Vermeulien A, Oddens BJ, editors. Androgens and the aging male. New York: Parthenon Publishing; 1996. p. 3-14.
46. Pines A. Male menopause: is it a real clinical syndrome? Climacteric. 2011;14:15-7.
47. Bove R. Autoimmune diseases and reproductive aging. Clin Immunol. 2013;149:251-64.
48. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab. 2005;90:3847-53.
49. Weiskopf D, Weinberger B, Grubeck-Loebenstein The aging of the immune system. Transpl Int. 2009;22:1041-50.
50. Gameiro CM, Romao F, Castelo-Branco C. Menopause and aging: changes in the immune system- a review. Maturitas. 2010;67:316-20.
51. Goronzy JJ, Weyand CM. Understanding immunose- nescence to improve responses to vaccines. Nat Immunol. 2013;14:428-36.
52. Blum M, Zacharovich D, Pery J, Kitai E. Lowering effect of estrogen replacement treatment on immunoglobulins in menopausal women. Rev Fr Gynecol Obstet. 1990;85:207-9.
53. White HD, Crassi KM, Givan AL, Stern JE, Gonzalez JL, Memoli VA, Green WR, Wira CR. CD3+ CD8+ CTL activity within the human female reproductive tract: influence of stage of the menstrual cycle and menopause. J Immunol. 1997;158:3017-27.
54. Shakhar K, Shakhar G, Rosenne E, Ben-Eliyahu S. Timing within the menstrual cycle, sex and the use of oral contraceptives determine adrenergic suppression of NK cell activity. Br J Cancer. 2000;83: 1630-6.
55. Evans MJ, Eckert A, Lai K, Adelman SJ, Harnish DC. Reciprocal antagonism between estrogen receptor and NF-KB activity in vivo. Circ Res. 2001;89: 823-30.
56. Demyanets S, Pfaffenberger S, Kaun C, Rega G, Speidl WA, Kastl SP, Weiss TW, Hohensinner PJ, Dietrich W, Tschugguel W, Bochkov VN, Awad EM, Maurer G, Huber K, Wojta J. The estrogen metabolite 17p-dihydroequilenin counteracts interleukin-1a induced expression of inflammatory mediators in human endothelial cells in vitro via NF-KB pathway. Thromb Haemost. 2006;95:107-16.
57. Feldman I, Feldman GM, Mobarak C, Dunkelberg JC, Leslie KK. Identification of proteins within the nuclear factor-kappa B transcriptional complex including estrogen receptor-alpha. Am J Obstet Gynecol. 2007;196:394.e1-11.
58. Paimela T, Ryhanen T, Mannermaa E, Ojala J, Kalesnykas G, Salminen A, Kaarniranta K. The effect of 17beta-estradiol on IL-6 secretion and NF-kappaB DNA-binding activity in human retinal pigment epithelial cells. Immunol Lett. 2007;110:139-44.
59. Liu H-B, Loo KK, Palaszynski I, Ashouri J, Lubahn DB, Voskuhl RR. Estrogen receptor a mediates estrogen’s immune protection in autoimmune disease. J Immunol. 2003;171:6936-40.
60. Streilein JW. Skin-associated lymphoid tissues (SALT): origins and functions. J Invest Dermatol. 1983;80:12S-6.
61. Bos JD, Kapsenberg ML. The skin immune system (SIS): its cellular constituents and their interactions. Immunol Today. 1986;7:235-40.
62. Nestle FO, Di Meglio P, Qin J-Z, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol. 2009;9:679-91.
63. Grice EA, Segre JA. The skin microbiome. Nat Rev Microbiol. 2011;9:244-53.
64. Heath WR, Carbone FR. The skin-resident and migratory immune system in steady state and memory: innate lymphocytes, dendritic cells and T cells. Nat Immunol. 2013;14:978-85.
65. Klechevsky E. Human dendritic cells- stars in the skin. Eur J Immunol. 2013;43:3147-55.
66. Harvima IT, Nilsson G. Mast cells as regulators of skin inflammation and immunity. Acta Derm Venereol. 2011;91:644-50.
67. Schauber J, Dorschner RA, Coda AB, Buchau AS, Liu PT, Kiken D, Helfrich YR, Kang S, Elalieh HZ, Steinmeyer A, Zugel U, Bikle DD, Modlin RL, Gallo RL. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest. 2007;117:803-11.
68. Feldmeyer L, Keller M, Niklaus G, Hohl D, Werner S, Beer H-D. The inflammasome mediates UVB- induced activation and secretion of interleukin-1 p by keratinocytes. Curr Biol. 2007;17:1140-5.
69. Wen H, Miao EA, Ting JP-Y. Mechanisms of NODlike receptor-associated inflammasome activation. Immunity. 2013;39:432-41.
70. Liew FY. IL-33: a Janus cytokine. Ann Rheum Dis. 2012;71(Supp II):1101-4.
71. Yu S-L, Wong C-K, Tam L-S. The alarmin functions of high-mobility group box-1 and IL-33 in the pathogenesis of systemic lupus erythematosus. Expert Rev Clin Immunol. 2013;9:739-49.
72. Imai Y, Yasuda K, Sakaguchi Y, Haneda T, Mizutani H, Yoshimoto T, Nakanishi K, Yamanishi K. Skin- specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci U S A. 2013;110:13921-6.
73. Philip NH, Artis D. New friendships and old feuds: relationships between innate lymphoid cells and microbial communities. Immunol Cell Biol. 2013;91: 225-31.
74. Pantelyushin S, Haak S, Ingold B, Kulig P, Heppner FL, Navarini AA, Vecher B. Roryt+ innate lymphocytes and y5 T cells initiate psoriasiform plaque formation in mice. J Clin Invest. 2012;122:2252-6.
75. Cai Y, Shen X, Ding C, Qi C, Li K, Li X, Jala VR, Zhang HG, Wang T, Zheng J, Yan J. Pivotal role of dermal IL-17-producing y5 T cells in skin inflammation. Immunity. 2011;35:596-610.
76. Kim BS, Siracusa MC, Saenz SA, Noti M, Monticelli LA, Sonnenberg GF, Hepworth MR, van Voorhees AS, Comeau MR, Artis D. TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci Transl Med. 2013;5:170ra116.
77. Martin SFF. Allergic contact dermatitis: xenoinflam- mation of the skin. Curr Opin Immunol. 2012;24: 720-9.
78. Fairweather D, Frisancho-Kiss S. Mast cells and inflammatory heart disease: potential drug targets. Cardiovasc Hematol Disord Drug Targets. 2008;8: 80-90.
79. Kennelly R, Conneely JB, Bouchier-Hayes D, Winter DC. Mast cells in tissue healing: from skin to the gastrointestinal tract. Curr Pharm Des. 2011;17:3772-5.
80. Frisancho-Kiss S, Nyland JF, Davis SE, Barrett MA, Gatewood SJL, Njoku DB, Cihakova D, Silbergeld EK, Rose NR, Fairweather D. Cutting edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity. J Immunol. 2006;176:6411-5.
81. Maurer M, Lopez Kostka S, Sievenhaar F, Moelle K, Metz M, Knop J, von Stebut E. Skin mast cells control T cell-dependent host defense in Leishmania major infections. FASEB J. 2006;20:2460-7.
82. Siebenhaar F, Syska W, Weller K, Magerl M, Zuberbier T, Metz M, Maurer M. Control of Pseudomonas aeruginosa skin infections in mice is mast cell-dependent. Am J Pathol. 2007;170:1910-6.
83. Metz M, Margeri M, Kuhl NF, Valeva A, Bhakdi S, Maurer M. Mast cells determine the magnitude of bacterial toxin-induced skin inflammation. Exp Dermatol. 2008;18:160-6.
84. Metz M, Piliponsky AM, Chen C-C, Lammel V, Abrink M, Pejler G, Tsai M, Galli SJ. Mast cells can enhance resistance to snake and honeybee venoms. Science. 2006;313:526-30.
85. Fairweather D, Frisancho-Kiss S, Yusung SA, Barrett MA, Davis SE, Gatewood SJL, Njoku DB, Rose NR. IFN-y protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines TGF-p1, IL-1p, and IL-4 in the heart. Am J Pathol. 2004;165:1883-94.
86. Huttunen M, Aalto M-L, Harvima RJ, Horsmanheimo M, Harvina IT. Alterations in mast cells showing tryptase and chymase activity in epithelializating and chronic wounds. Exp Dermatol. 2000;9:258-65.
87. Weller K, Foitzik K, Paus R, Syska W, Maurer M. Mast cells are required for normal healing of skin wounds in mice. FASEB J. 2006;20:2366-8.
88. Irani A-MA, Bradford TR, Kepley CL, Schechter NM, Schwartz LB. Detection of MCT and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. J Histochem Cytochem. 1989;37:1509-15.
89. Mizutani H, Schechter NM, Lazarus G, Clack RA, Kupper TS. Rapid and specific conversion of precursor interleukin 1p (IL-1p) to an active IL-1 species by human mast cell chymase. J Exp Med. 1991;174:821-5.
90. Omoto Y, Tokime K, Yamanaka K, Habe K, Morioka T, Kurokawa I, Tsutsui H, Yamanishi K, Nakanishi K, Mizutani H. Human mast cell chymase cleaves pro- IL-18 and generates a novel and biologically active IL-18 fragment. J Immunol. 2006;177:8315-9.
91. Pullen NA, Falangea YT, Morales JK, Ryan JJ. The Fyn-STAT5 pathway: a new frontier in IgE- and IgG-mediated mast cell signaling. Front Immunol. 2012;3:117.
92. Lavie CJ, Lee JH, Milani RV. Vitamin D and cardiovascular disease: will it live up to the hype? J Am Coll Cardiol. 2011;58:1547-56.
93. Plum LA, DeLuca HF., Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Disc. 2010;9: 941-55.
94. Zittermann A, Gummert JF. Sun, vitamin D, and cardiovascular disease. J Photochem Photobiol. 2010; 101:124-9.
95. Norman AW. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology. 2006;147:5542-8.
96. Mason RS, Reichrath J. Sunlight vitamin D and skin cancer. Anti-Cancer Agents Med Chem. 2013;13: 83-97.
97. Bikle DD. Vitamin D regulation of immune function. In: Litwack G, editor. Vitamins and hormones: vitamins and the immune system, vol. 86. Amsterdam: Elsevier; 2011. p. 1-21.
98. Onyimba JA, Coronado MJ, Garton AE, Kim JB, Bucek A, Bedja D, Gabrielson KL, Guilarte TR, Fairweather D. The innate immune response to coxsackievirus B3 predicts progression to cardiovascular disease and heart failure in male mice. Biol Sex Differ. 2011;2:2.
99. Lisse TS, Hewison M, Adams JS. Hormone response element binding proteins: novel regulators of vitamin D and estrogen signaling. Steroids. 2011;76:331-9.
100. Litwack G, editor. Vitamins and hormones: vitamins and the immune system, vol. 86. Amsterdam: Elsevier; 2011.
101. Topiliski I, Flaishon L, Naveh Y, Harmelin A, Levo Y, Shacher I. The anti-inflammatory effects of 1,25-dihydroxyvitamin D3 on Th2 cells in vivo are due in part to the control of integrin-mediated T lymphocyte homing. Eur J Immunol. 2004;34:1068-76.
102. Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM, Adorini L. Regulatory T cells induced by 1 alpha,25-dihydroxyviatin D3 and mycopheno- late mofetil treatment mediate transplantation tolerance. J Immunol. 2001;167:1945-53.
103. Daniel C, Sartory NA, Zahn N, Radeke HH, Stein JM. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther. 2008;324:23-33.
104. Rook GA, Steele J, Fraher L, Barker S, Karmiali R, O’Riordan J, Stanford J. Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monoctyes. Immunology. 1986;57:159-63.
105. Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, Tavera-Mendoza L, Lin R, Hanrahan JW, Mader S, White JH. Cutting edge: 1,25-dihydroxyvi- tamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004;173:2909-12.
106. Baroni E, Biffi M, Benigni F, Monno A, Carlucci D, Carmeliet G, Bouillon R, D’Abrosio D. VDR- dependent regulation of mast cell maturation mediated by 1,25-dihydroxyvitamin D3. J Leukoc Biol. 2007;81:250-62.
107. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Shauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hweison M, Hollis BW, Adams JS, Bloom BR, Modlin RL. Tolllike receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006; 311:1770-3.
108. Liu PT, Stenger S, Tan DH, Modlin RL. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol. 2007;179:2060-3.
109. Spach KM, Hayes CE. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol. 2005;175:4119-26.
110. Brehm JM, Schuemann B, Fuhlbrigge AL, Hollis BW, Strunk RC, Zeiger RS, Weiss ST, Litonjua AA. Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study. J Allergy Clin Immunol. 2010; 126:52-8.
111. Wittke A, Weaver V, Mahon BD, August A, Cantorna MT. Vitamin D receptor-deficient mice fail to develop experimental allergic asthma. J Immunol. 2004;173:3432-6.
112. Looker AC, Johnson CL, Lacher DA, Pfeiffer CM, Schleicher RL, Sempos CT. Vitamin D status: United States, 2001-2006. NCHS Data Brief. 2011; 59:1-8.
113. Ross AC, Taylor CL, Yaktine AL, Del Valle HB, editors. Dietary reference intakes: calcium and vitamin D. Washington, DC: The National Academies Press; 2011.
114. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008; 168:1629-37.
115. Cutolo M. Vitamin D and autoimmune rheumatic diseases. Rheumatology (Oxford). 2009;48:210-2.
116. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol. 2010;9:599-612.
117. Muller K, Kriegbaum NJ, Baslund B, Sorensen OH, Thymann M, Bentzen K. Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 12-hydroxyvitamin D3 in patients with systemic lupus erythematosus. J Clin Rheumatol. 1995;14:397-400.
118. Cutolo M, Plebani M, Shoenfeld Y, Adorini L, Tincani A. Vitamin D endocrine system and the immune response in rheumatic diseases. In: Latwick G, editor. Vitamins and hormones: vitamins and the immune system. Amsterdam: Elsevier; 2011. p. 327-51.
119. Clemens TL, Adams JS, Henderson SL, Holick MF. Increased skin pigment reduces the capacity of skin to synthesize vitamin D3. Lancet. 1982;1:74-6.
120. Tang JY, Fu T, Lau C, Oh DH, Bikle DD, Asgari MM. Vitamin D in cutaneous carcinogenesis. J Am Acad Dermatol. 2012;67:803.e1-12.
121. Kronbichler A, Mayer G. Renal involvement in autoimmune connective tissue diseases. BMC Med. 2013;11:95.
122. Lemire JM, Ince A, Takashima M. 1,25-Dihydro- xyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. Autoimmunity. 1992;12:143-8.
123. Schoenfeld N, Amital H, Shoenfeld Y. The effect of melanism and vitamin D synthesis on the incidence of autoimmune disease. Nat Clin Pract Rheumatol. 2009;5:99-105.
124. Oelzner P, Muller A, Deschner F, Huller M, Abendroth K, Hein G, Stein G. Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int. 1998;62:193-8.
125. Cutolo M, Otsa K, Laas K, Yprus M, Lehtme R, Secchi ME, Sulli A, Paolino S, Seriolo B. Circannual vitamin D serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. Clin Exp Rheumatol. 2006;24:702-4.
126. Andjelkovic Z, Vojinovic J, Pejnovic N, Popovic M, Dujic A, Mitrovic D, Pavlica L, Stefanovic D. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol. 1999;17:453-6.
127. Zold E, Barta Z, Bodolay E. Vitamin D deficiency and connective tissue disease. In: Latwick G, editor. Vitamins and hormones: vitamins and the immune system. Amsterdam: Elsevier; 2011. p. 261-86.
128. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydrooxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr. 1998;128:68-72.
129. Larsson P, Mattsson L, Klareskog L, Johnsson C. A vitamin D analogue (MC 1288) has immunomodulatory properties and suppresses collagen-induced arthritis (CIA) without causing hyper calcaemia. Clin Exp Immunol. 1998;114:277-83.
130. Huckins D, Felson DT, Holick M. Treatment of psoriatic arthritis with oral 1,25-dihydroxyvitamin D3: a pilot study. Arthritis Rheum. 1990;33:1723-7.
131. Gaal J, Lakos G, Szodoray P, Kiss J, Horvath I, Horkay E, Nagy G, Szegedi A. Immunological and clinical effects of alphacalcidol in patients with psoriatic arthropathy: results of an open, follow-up pilot study. Acta Derm Venereol. 2009;89:140-4.
132. Dayangac-Erden D, Karaduman A, Erdem-Yurter H. Polymorphisms of vitamin D receptor gene in Turkish familial psoriasis patients. Arch Dermatol Res. 2007;99:487-91.
133. Zold E, Szodoray P, Gaal J, Kappelmayer J, Csathy L, Gymesi E, Zeher M, Szegedi G, Bodolay E. Vitamin D deficiency in undifferentiated connective tissue disease. Arthritis Res Ther. 2008;10: R123.
134. Calzolari G, Data V, Carignola R, Angeli A. Hypo- vitaminosis D in systemic sclerosis. J Rheumatol. 2009;36:2844.
135. Vacca A, Cormier C, Piras M, Mathieu A, Kahan A, Allanore Y. Vitamin D deficiency and insufficiency in 2 independent cohorts of patients with systemic sclerosis. J Rheumatol. 2009;36:1924-9.
136. Caramaschi P, Dalla GA, Ruzzenente O, Volpe A, Rvagnani V, Tinazzi I, Barausse G, Bambara LM, Biasi D. Very low levels of vitamin D in systemic sclerosis patients. Clin Rheumatol. 2010;29:1419-25.
137. Artaza JN, Norris KC. Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells. J Endocrinol. 2009;200:207-21.
138. Muller K, Oxholm P, Sorensen OH, Thymann M, Hoier-Madsen M, Bendtzen K. Abnormal vitamin D3 metabolism in patients with primary Sjogren’s syndrome. Ann Rheum Dis. 1990;49:682-4.
139. Bang B, Asmussen K, Sorensen OH, Oxholm P. Reduced 25-hydroxyvitamin D levels in primary Sjogren’s syndrome. Correlations to disease manifestations. Scand J Rheumatol. 1999;28:180-3.
140. Aguado P, del Campo MT, Garces MV, Gonzalez- Casaus ML, Bernad M, Gijon-Banos J, Martin Mola E, Torrijos A, Martinez ME. Low vitamin D levels in outpatient postmenopausal women from a rheumatology clinic in Madrid, Spain: their relationship with bone mineral density. Osteoporos Int. 2000;11: 739-44.
141. Lagunova Z, Porojnicu AC, Lindberg F, Hexeberg S, Moan J. The dependency of vitamin D status on body mass index, gender, age and season. Anticancer Res. 2009;29:3710-20.
142. Need AG, Morris HA, Horowitz M, Nordin Effects of skin thickness, age, body fat, and sunlight on serum 25-hydroxyvitamin D. Am J Clin Nutr. 1993;58:882-5.
143. Nordin BE, Polley KJ. A cross-sectional, longitudinal, and intervention study on 557 normal postmenopausal women. Calcif Tissue Int. 1987;41 Suppl 1: S1-59.
144. Webb AR, Pilbean C, Hanafin N, Holick MF. An evaluation of the relative contributions of 25-hydroxyvitamin D in an elderly nursing home ooulation in Boston. Am J Clin Nutr. 1990;51: 1075-81.
145. Gonzalez G, Alvarado JN, Rojas A, Navarrete C, Velasquez CG, Arteaga E. High prevalence of vitamin D deficiency in Chilean healthy postmenopausal women with normal sun exposure: additional evidence for a worldwide concern. Menopause. 2007;14:455-61.
146. Vieth R, Ladak Y, Walfish PG. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab. 2003;88:185-91.
147. Hocher B, Reichetzeder C. Vitamin D and cardiovascular risk in postmenopausal women: how to translate preclinical evidence into benefit for patients. Kidney Int. 2013;84:9-11.
148. Sticherling M. Lupus erythematosus: chronic cutaneous lupus erythematosus. In: Hertl M, editor. Autoimmune diseases of the skin. 3rd ed. Vienna: Springer-Verlag; 2011. p. 193-213.
149. Pellowski DM, Kihslinger JE, Sontheimer RD. Lupus erythematosus: subacute cutaneous and systemic lupus erythematosus. In: Hertl M, editor. Autoimmune diseases of the skin. 3rd ed. Vienna: Springer-Verlag; 2011. p. 216-41.
150. Costner MI, Sontheimer RD, Provost TT. Lupus erythematosus. In: Sontheimer RD, Provost TT, editors. Cutaneous manifestations of rheumatic diseases. Philadelphia: Williams and Wilkins; 2003. p. 15-64.
151. Southheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol. 1979;115:1409-15.
152. Tan TC, Fang H, Magder LS, Petri MA. Differences between male and female systemic lupus erythematosus in a multiethnic population. J Rheumatol. 2012;39:759-69.
153. Kind P, Lehmann P, Plewig G. Phototesting in lupus erythematosus. J Invest Dermatol. 1993;100:53S-7.
154. Mond CB, Perterson MG, Rothfield NF. Correlation of anti-Ro antibody with photosensitivity rash in systemic lupus erythematosus patients. Arthritis Rheum. 1989;32:202-4.
155. Nasti TH, Timares L. Inflammasome activation of IL-1 family mediators in response to cutaneous photodamage. Photchem Photobiol. 2012;88:1111-25.
156. Frances C, Kluger N. Skin manifestations of rheumatic diseases. In: Sontheimer RD, Provost TT, editors. Cutaneous manifestations of rheumatic diseases. Philadelphia: Williams and Wilkins; 2011. p. 405-33.
157. Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Rowert J, AUdring H, Kary S, Burmester GR, Sterry W, Worm M. Cutaneous side-effects in patients with rheumatic disease during application of tumour necrosis factor-alpha antagonists. Br J Dermatol. 2007;156:486-91.
158. Fox RI, Fox CM. Sjogren’s syndrome. In: Sontheimer RD, Provost TT, editors. Cutaneous manifestations of rheumatic diseases. Philadelphia: Williams and Wilkins; 2011. p. 283-324.
159. Alexander EL, Provost TT. Cutaneous manifestations of primary Sjogren’s syndrome: a reflection of vasculitis and association with anti-Ro (SSA) antibodies. J Invest Dermatol. 1983;80:386-91.
160. Tappinos NI, Plihronis M, Tziofas AG, Moutsopoulos HM. Sjogern’s syndrome. Autoimmune epithelitis. Adv Exp Med Biol. 1999;455:127-34.
161. Fox RI, Chen PP, Carson DA, Fong S. Expression of a cross reactive idiotype on rheumatoid factor in patients with Sjogren’s syndrome. J Immunol. 1986;136:477-83.
162. Kyle R, Gleich G, Baynd E, Vaughan JH. Benign hyperglobulinemic purpura of Waldenstrom. Medicine (Baltimore). 1971;50:113-23.
163. Vleugels RA, Callen JP. Dermatomyositis. In: Hertl M, editor. Autoimmune diseases of the skin. 3rd ed. Vienna: Springer-Verlag; 2011. p. 243-66.
164. Kellet CV, Orteu H, Dutz JP. Scleroderma: localized scleroderma. In: Sontheimer RD, Provost TT, editors. Cutaneous manifestations of rheumatic diseases. Philadelphia: Williams and Wilkins; 2011. p. 137-72.
165. Hunzelmann N, Krieg T. Scleroderma: progressive systemic scleroderma. In: Sontheimer RD, Provost TT, editors. Cutaneous manifestations of rheumatic diseases. Philadelphia: Williams and Wilkins; 2011. p. 173-91.
166. Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, Connolly MK, Whitfield ML. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One. 2008;3:e2696.
167. Whittaker SJ, Smith NP, Jones RR. Solitary mor- phoea profunda. Br J Dermatol. 1989;120:431-40.
168. Antiga E, Quaglino P, Bellandi S, Volpi W, Del Bianco E, Comessatti A, Osella-Abate S, De Simone C, Marzano A, Bernengo MG, Fabbri P, Caproni M. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br J Dermatol. 2010;162:1056-63.
169. Aiba S, Tabata N, Ohtani H, Tagami H. Cd34+ spindle-shaped cells selectively disappear from the skin lesion of scleroderma. Arch Dermatol. 1994;130: 593-7.
170. Kubo M, Ihn H, Yamane K, Tamaki K. Up-regulated expression of transforming growth factor beta receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum. 2001;44:731-4.
171. Ihn H, Sato S, Fujimoto M, Kikuchi K, Takehara K. Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res. 1995;287:193-7.
172. Hasegawa M, Sato S, Nagaoka T, Fujimoto M, Takehara K. Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma. Dermatology. 2003;207:141-7.
173. Shanmugam VK, Swistowski DR, Saddic N, Wang H, Steen VD. Comparison of indirect immunofluorescence and multiplex antinuclear antibody screening in systemic sclerosis. Clin Rheumatol. 2011;30: 1363-8.
174. Schwartzman-Morris J, Putterman C. Gender differences in the pathogenesis and outcome of lupus and lupus nephritis. Clin Dev Immunol. 2012;2012: 604892.
175. Sammaritano LR. Menopause in patients with autoimmune diseases. Autoimmun Rev. 2012; 11: A430-6.
176. Font J, Pallares L, Cervera R, Lopez-Soto A, Navarro M, Bosch X, Ingelmo M. Systemic lupus onset in the elderly: clinical and immunological characteristics. Ann Rheum Dis. 1991;50:702-5.
177. Ho CTK, Mok CC, Lau CS, Wong RWS. Late onset systemic lupus erythematosus in southern Chinese. Ann Rheum Dis. 1998;57:437-40.
178. Peterson LS, Nelson AM, Su WP, Mason T, O’Fallon WM, Gabriel SE. The epidemiology of morphea localized scleroderma in Olmstead County 19601993. J Rheumatol. 1997;24:73-80.
179. Wang J, Nuite M, McAlindon TE. Association of estrogen and aromatase gene polymorphisms with systemic lupus erythematosus. Lupus. 2010;19: 734-40.
180. Lu L-J, Wallace DJ, Ishimori ML, Scofield RH, Weisman MH. Male systemic lupus erythematosus: a review of sex disparities in this disease. Lupus. 2010;19:119-29.
181. Akahoshi M, Nakashima H, Tanaka Y, Kohsaka T, Nagano S, Ohgami E, Arinobu Y, Yamaoka K, Niiro H, Shinozaki M, Hirakata H, Horiuchi T, Otsuka T, Niho Y. Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum. 1999;42:1644-8.
182. Palma G, Barbieri A, Bimonte S, Palla M, Zappavigna S, Caraglia M, Ascierto PA, Ciliberto G, Arra C. Interleukin 18: friend or foe in cancer. Biochem Biophys Acta. 2013;1836:296-303.
183. Wang Y, Meng J, Wang X, Liu S, Shu Q, Gao L, Ju Y, Zhang L, Sun W, Ma C. Expression of human TIM-1 and TIM-3 on lymphocytes from systemic lupus erythematosus patients. Scand J Immunol. 2007;67:63-70.
184. Boddaert J, Huang DLT, Amoura Z, Wechler B, Godeau P, Piette JC. Late onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine. 2004;83:348-59.
185. Mok CC, Lau CS, Ho CT, Wong RW. Do flares of systemic lupus erythematosus decline after menopause? Scand J Rheumatol. 1999;28:357-62.
186. Sanchez-Guerrero J, Villegas A, Mendoza-Feuntes A, Romero-Diaz J, Moreno-Coutino G, Cravioto MC. Disease activity during the premenopausal and post menopausal periods in women with SLE. Am J Med. 2001;111:464-8.
187. Namjou B, Scofield RH, Kelly JA, Goodman EL, Aberle T, Bruner GR, Harley JB. The effects of previous hysterectomy on lupus. Lupus. 2009;18: 1000-5.
188. Cooper GS, Dooley MA, Treadwell EL, St Claire W, Gilkeson GS. Hormonal and reproductive risk factors for development of SLE: results of a population based case-control study. Arthritis Rheum. 2002;46:1830-9.
189. Costenbader KH, Feskanich D, Stampfer MJ, Kalson EW. Reproductive and menopausal factors and risk of SLE in women. Arthritis Rheum. 2007;56: 1251-62.
190. Buyon JP, Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Merrill JT, Sammaritano L, Lockshin M, Alarcon GS, Manzi S, Belmont HM, Askanase AD, Sigler L, Dooley MA, von Feldt J, McCune WJ, Friedman A, Wachs J, Cronin M, Hearth-Holmes M, Tan M, Licciardi F. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus. Ann Intern Med. 2005;142: 953-62.
191. Urowitz MB, Ibanez D, Jerome D, Gladman DD. The effect of menopause on disease activity in systemic lupus erythematosus. J Rheumatol. 2006; 33:2193-8.
192. Fernandez M, Calvo-Alen J, Alarcon G, Roseman JM, Bastian HM, Fessler BJ, McGwin Jr G, Vila LM, Sanchez ML, Reveille JD. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre-and postmenopausal women. Arthritis Rheum. 2005;52:1655-64.
193. Sticherling M. Systemic sclerosis- dermatological aspects. Part 1: pathogenesis, epidemiology, clinical findings. J Dtsch Dermatol Ges. 2012;10:705-18.
194. Toms TE, Panoulas VF, Kitas GD. Dyslipidaemia in rheumatological autoimmune diseases. Open Cardiov Med J. 2011;5:64-75.
195. Au K, Singh MK, Bodukam V, Bae S, Maranian P, Ogawa R, Spiegel B, McMahon M, Hahn B, Khanna Atherosclerosis in systemic sclerosis: a systemic review and meta-analysis. Arthritis Rheum. 2011;63: 2078-90.
196. Viswanath V, Phiske MM, Gopalani VV. Systemic sclerosis: current concepts in pathogenesis and therapeutic aspects of dermatological manifestations. Indian J Dermatol. 2013;58:255-68.
197. Greenblatt MB, Aliprantis AO. The immune pathogenesis of scleroderma: context is everything. Curr Rheumatol Rep. 2013;15:297.
198. Battacharyya S, Kelly K, Melichian DS, Tamaki Z, Fang F, Su Y, Feng G, Pop RM, Budinger GRS, Mutlu GM, Lafyatis R, Tadstake T, Feghali- Bostwick C, Varga J. Toll-like receptor 4 signaling augments transforming growth factor-p responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J Pathol. 2013;182: 192-205.
199. Giuggioli D, Manfredi A, Colaci M, Manzini CU, Antonelli A, Ferri C. Systemic sclerosis and cryogl- bulinemia: our experience with overlapping syndrome of scleroderma and sever cryoglobulinemic vasculitis and review of the literature. Autoimmun Rev. 2013;12:1058-63.
200. Reddi DM, Cardona DM, Burchette JL, Puri PK. Scleroderma and IgG4-related disease. Am J Dermatopathol. 2013;35:458-62.
201. Quemeneur T, Mouthon L, Cacoub P, Meyer O, Michon-Pasturel U, Vanhille P, Hatron P-Y, Guillevin L, Hachull E. Systemic vasculitis during the course of systemic sclerosis: report of 12 cases and review of the literature. Medicine. 2013;92:1-9.
202. Nguyen C, Berenzne A, Baubet T, Mestre-Stanislas C, Rannou F, Papelard A, Merell-Dubois S, Revel M, Guillevin L, Poiraudeau S, Mouthon L, Groupe Francais de recherche sur la Sclerodermie. Association of gender with clinical expression, quality of life, disability, and depression and anxiety in patients with systemic sclerosis. PLoS One. 2011;6:e17551.
203. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41:778.
204. Loucks J, Pope JE. Osteoporosis in scleroderma. Semin Arhtits Rheum. 2004;34:678-82.
205. Pikwer M, Nilsson J-A, Bergstrom U, Jacobsson LTH, Turesson C. Early menopause and severity of rheumatoid arthritis in women older than 45 years. Arthritis Res Ther. 2012;14: R190.
206. Deal CL, Meenan RF, Goldenberg DL, Anderson JT, Sack B, Pastan RS, et al. The clinical features of elderly-onset rheumatic arthritis: a comparison with younger onset disease of similar duration. Arthritis Rheum. 1985;28:987-94.
207. Turkcapar N, Demir O, Atli T, Kopuk M, Turgay M, Kinikli G, et al. Late onset rheumatoid arthritis: clinical and laboratory comparisons with younger onset patients. Arch Gerontol Geriatr. 2006;42:225-31.
208. Nielsen RH, Christiansen C, Stolina M, Karsdal MA. Oestrogen exhibits type II collagen protective effects and attenuates collagen-induced arthritis in rats. Clin Exp Immunol. 2008;152:21-7.
209. Dolhain RJ, van der Heiden AN, ter Haar NT, Breedveld FC, Miltenburg AM. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum. 1996;39:1961-9.
210. Haddad A, Bienvenu J, Moissec P. Increased production of a Th2 cytokine profile by activated whole blood cells from rheumatoid arthritis patients. J Clin Immunol. 1998;18:399-403.
211. Van Roon JA, Verhoef CM, van Roy JL, Gmelig- Meyling FH, Huber-Bruning O, Lafever FP, Bijlsma JW. Decrease in peripheral type 1 over type 2 T cell cytokine production in patients with rheumatoid arthritis correlates with an increase in severity of disease. Ann Rheum Dis. 1997;56:656-60.
212. Ostenson M, Aune B, Husby G. Effect of pregnancy and hormonal changes on the activity of rheumatoid arthritis. Scand J Rheumatol. 1983;12:69-72.
213. Silman A, Kay A, Brennan P. Timing of pregnancy in relation to the onset of rheumatoid arthritis. Arthritis Rheum. 1992;35:152-5.
214. Hughes GC. Progesterone and autoimmune disease. Autoimmun Rev. 2012;11: A502-14.
215. Latman NS. Relation of menstrual cycle phase to symptoms of rheumatoid arthritis. Am J Med. 1983; 74:957-60.
216. Linos A, Worthington JW, O’Fallon WM, Kurland LT. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am J Epidemiol. 1980;111:87-98.
217. Dugowson CE, Koepsell TD, Voigt LF, Bley L, Nelson JL, Daling JR. Rheumatoid arthritis in women: incidence rate in group health cooperative, Seattle, Washington, 1987-1989. Arthritis Rheum. 1991;34:1502-7.
218. Brennan P, Bankhead C, Silman A, Symmons D. Oral contraceptives and rheumatoid arthritis: results from a primary care-based incident case-control study. Semin Arthritis Rheum. 1997;26:817-23.
219. Hannaford PC, Kay CR, Hirsch S. Oral contraceptives and rheumatoid arthritis: new data from the Royal College of General Practitioners’ oral contraception study. Ann Rheum Dis. 1990;49:744-6.
220. Vandenbroucke JP, Valkenburg HA, Boersma JW, Cats A, Festen JJ, Huber-Bruning O, Rasker JJ. Oral contraceptives and rheumatoid arthritis: further evidence for a preventative effect. Lancet. 1982;2:839-42.
221. Costenbader KH, Manson JE. Do female hormones affect the onset or severity of rheumatoid arthritis? Arthritis Rheum. 2008;59:299-301.
222. Wallace DJ. The Sjogren’s Book. Oxford: Oxford University Press; 2012.
223. Mackay IR. Pathogenesis of Sjogrens. In: Wallace DJ, editor. The Sjogren’s book. Oxford: Oxford University Press; 2012. p. 17-30.
224. Tegner P, Halse AK, Haga HJ, Jonsson R, Wahren- Herlenius M. Detection of anti-Ro/SSA and anti-La/SSB autoantibody-producing cells in salivary glands from patients with Sjogren’s syndrome. Arthritis Rheum. 1998;41:2238-48.
225. Fox RI. Sjogren’s syndrome. Lancet. 2005;366: 321-31.
226. Diaz-Lopez C, Geli C, Corominas H, Malat N, Diaz- Torner C, Llobet JM, de la Serna AR, Laiz A, Moreno M, Vasquez G. Are there clinical or serological differences between male and female patients with primary Sjogren’s syndrome? J Rheumatol. 2004;31:1352-5.
227. Brennan M, Fox P. Sex differences in primary Sjogren’s syndrome. J Rheumatol. 1999;26:2373-6.
228. Drosos A, Tsiakou E, Tsifetaki N, Politi EN, Siamopoulou-Mavridou A. Subgroups of primary Sjogren’s syndrome. Sjogren’s syndrome in male and pediatric Greek patients. Ann Rheum Dis. 1997;56:333-5.
229. Horvath IF, Szodoray P, Zeher M. Primary Sjogren’s syndrome in men: clinical and immunological characteristics based on a large cohort of Hungarian patients. Clin Rheumatol. 2008;27:1479-83.
230. Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, Jimenez-Alonso J, Mico ML, Beltran J, Belenguer R, Pallares L, GEMESS Study Group. Primary Sjogren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore). 2008;87:210-9.
231. Molina R, Provost T, Arnett F, Bias WB, Hochberg MC, Wilson RW, Alexander EL. Primary Sjogren’s syndrome in men. Clinical, serologic, and immuno- genetic features. Am J Med. 1986;80:23-31.
232. Goeb V, Salle V, Duhaut P, Jouen F, Smail A, Ducroix J-P, Tron F, Le Loet X, Vittecoq O. Clinical significance of autoantibodies recognizing Sjogren’s syndrome A (SSA), SSB, calpastatin, and alpha-fodrin in primary Sjogren’s syndrome. Clin Exp Immunol. 2007;148:281-7.
233. Allan TR, Parke A. Gynecological issues, including pregnancy. In: Wallace DJ, editor. The Sjogren’s book. Oxford: Oxford University Press; 2012. p. 113-23.
234. Toda I, Sullivan BD, Rocha EM, da Silveira LA, Wickham LA, Sullivan DA. Impact of gender on exocrine gland inflammation in mouse models of Sjogren’s syndrome. Exp Eye Res. 1999;69:355-66.
235. Cihakova D, Talor MV, Barin JG, Baldeviano GC, Fairweather D, Rose NR, Burek CL. Sex differences in a murine model of Sjorgren syndrome. Ann NY Acad Sci. 2009;1173:378-83.
236. Mostafa S, Seamon V, Azzarolo AM. Influence of sex hormones and genetic predisposition in Sjogren’s syndrome: a new clue to the immunopathogenesis of dry eye disease. Exp Eye Res. 2012;96:88-97.
237. Toda I, Sullivan BD, Wickham LA, Sullivan DA. Gender- and androgen-related influence on the expression of proto-oncogene and apoptotic factor mRNAs in lacrimal glands of autoimmune and nonautoimmune mice. J Steroid Biochem Mol Biol. 1999;71:49-61.
238. Konttinen YT, Fuellen G, Bing Y, Porola P, Stegaev V, Trokovic N, Falk SSI, Szodoray P, Takakubo Y. Sex steroids in Sjogren’s syndrome. J Autoimmun. 2012;39:49-56.
239. Agha-Hosseini F, Mirzaii-Dizgah I, Mansourian A, Khayamzadeh M. Relationship of stimulated saliva 17beta-estradiol and oral dryness feeling in menopause. Maturitas. 2009;62:197-9.
240. Michael D, Soi S, Cabera-Perez J, Weller M, Alexander S, Alevizos I, Illei GG, Chiorini JA. Microarray analysis of sexually dimorphic gene expression in human minor salivary glands. Oral Dis. 2011;17:653-61.
241. Nandula SR, Amarnath S, Molinolo A, Bandyopadhyay BC, Hall B, Goldsmith CM, Zheng C, Larsson J, Sreenath T, Chen W, Ambudkar IS, Karlsson S, Baum BJ, Kulkarni AB. Female mice are more susceptible to developing inflammatory disorders due to impaired transforming growth factor p signaling in salivary glands. Arthritis Rheum. 2007;56:1798-805.
242. Rocha EM, Wickham LA, Huang Z, Toda I, Gao J, da Silveira LA, Sullivan DA. Presence and testosterone influence on the levels of anti- and proinflammatory cytokines in lacrimal tissues of a mouse model of Sjogren’s syndrome. Adv Exp Med Biol. 1998;438:485-91.
243. Valtysdottir ST, Wide L, Hallgren R. Low serum dehydroepiandrosterone sulfate in women with primary Sjogren’s syndrome as an isolated sign of impaired HPA axis function. J Rheumatol. 2001; 28:1259-65.
244. Forsblad-d’Elia H, Carlsten H, Labrie F, Konttinen YT, Ohlsson C. Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren’s syndrome: supplementation with dehydro- epiandrosterone restores the concentrations. J Clin Endocrinol Metab. 2009;94:2044-51.
245. Chen YT, Lazarev S, Bahrami AF, Noble LB, Chen FY, Zhou D, Gallup M, Yadav M, McNamara NA. Interleukin-1 receptor mediates the interplay between CD4+ T cells and ocular resident cells to promote keratinizing squamous metaplasia in Sjogren’s syndrome. Lab Invest. 2012;92:556-70.
246. Yamada A, Arakaki R, Kudo Y, Ishimaru N. Targeting IL-1 in Sjogren’s syndrome. Exp Opin Ther Targets. 2013;17:393-401.
247. Perrier S, Coussediere C, Dubost JJ, Albuisson E, Sauvezie B. IL-1 receptor antagonist (IL-1RA) gene polymorphism in Sjogren’s syndrome and rheumatoid arthritis. Clin Immunol Immunopathol. 1998;87: 309-13.
248. Muraki Y, Tsutsumi A, Takahashi R, Suzuki E, Hayashi T, Chino Y, Goto D, Matsumoto I, Murata H, Noguchi E, Sumida T. Polymorphisms of IL-1 beta gene in Japanese patients with Sjogren’s syndrome and systemic lupus erythematosus. J Rheumatol. 2004;31:720-5.
249. Bombardieri M, Barone F, Pittoni V, Alessandri C, Conigliaro P, Blades MC, Priori R, McInnes IB, Valesini G, Pitzalis C. Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjogren’s syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate. Arthritis Res Ther. 2004;6: R447-56.
250. Spadaro A, Rinaldi T, Riccieri V, Taccari E, Valesini G. Interleukin-13 in autoimmune rheumatic diseases: relationship with the autoantibody profile. Clin Exp Rheumatol. 2002;20:213-6.